FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development

FDA's pending guidance on clinical trials for antibiotics to treat hospital- and ventilator-acquired pneumonia can't help but add a measure of stability to the uncertain regulatory environment in the field, but stakeholders fear that when the clouds part, the view will be of a very high bar.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet